366. Association Between Gut Microbiota and Health-Related Quality of Life in Patients with Recurrent Clostridioides difficile Infection: Results from the PUNCH CD3 Clinical Trial
Authors: Feuerstadt Paul , Blount Ken , Guo Amy , Yang Min , García-Horton Viviana , Fillbrunn Mirko , Tillotson Glenn S , Gao Yipeng , Dubberke Erik R , Garey Kevin W 
Published: November 2023

Background

Recurrence of Clostridioides difficile infection (rCDI) substantially diminishes patients’ health-related quality of life (HRQL). The gut microbiome is known to play an important role in rCDI, but little is known about its relationship with HRQL. In this study, we assessed the relationship between the gut microbiome and HRQL in patients with rCDI from REBYOTA’s (fecal microbiota, live-jslm [RBL]) phase 3 PUNCH CD3 trial (NCT03244644).

Methods

HRQL and relative abundance (i.e., the % of one microbiota relative to all other analyzed) of gut microbiota at the class level were collected at baseline and weeks 1, 4, and 8. The Microbiome Health Index (MHI; Blount et al, 2022), defined as (Bacteroidia + Clostridia) / (Gammaproteobacteria + Bacilli), was analyzed using log transformation and as a binary indicator with MHI &gt; 7.2 indicating a healthy microbiome. HRQL was measured using the disease-specific C. difficile Quality of Life Survey (Cdiff32) via its total score and physical, mental, and social domain scores (0–100 range, 100 best).

Correlations between microbiota data (Bacteroidia, Clostridia, Gammaproteobacteria, Bacilli, and log MHI) and Cdiff32 scores were estimated. Associations of Cdiff32 scores with microbiota data and MHI &gt; 7.2 were estimated using mixed effects analyses adjusted for baseline patient characteristics. Analyses used all available data (baseline, weeks 1, 4, 8). P-values were adjusted for multiple testing via the Benjamini-Hochberg procedure; correlations were interpreted as moderate if ≥ 0.3 and large if ≥ 0.5 (Cohen, 1988).

Results

A total of 176 out of 262 (67.2%) patients had Cdiff32 and microbiota data (119 RBL, 57 Placebo) in PUNCH CD3. All four Cdiff32 scores correlated positively with log MHI (∼0.6), Clostridia (∼0.5) and Bacteroidia (∼0.3), and negatively with Gammaproteobacteria (∼−0.5) and Bacilli (∼−0.3) (Table 1). Significant associations of microbial relative abundances and log MHI with all Cdiff32 scores were found in mixed effects analyses (all p&lt; 0.01) (Table 2). MHI &gt; 7.2 (healthy microbiome) was associated with an improvement of 14.2 to 18.4 points in Cdiff32 scores (vs. MHI ≤ 7.2).

Conclusion

Our study found moderate to large and statistically significant associations between a healthy gut microbiome and improved HRQL in patients with rCDI.

Disclosures

Paul Feuerstadt, MD, FACG, AGAF, Ferring/Rebiotix Pharmaceuticals: Advisor/Consultant|Ferring/Rebiotix Pharmaceuticals: Grant/Research Support|Merck and Co.: Advisor/Consultant|Seres Therapeutics: Advisor/Consultant|Seres Therapeutics: Grant/Research Support|Takeda Pharmaceuticals: Advisor/Consultant Ken Blount, PhD, Ferring Pharmaceuticals: Employee Amy Guo, PhD, Ferring Pharmaceuticals: Employee Min Yang, MD, PhD, Analysis Group, Inc.: I am an employee of Analysis Group, Inc., which has received consulting fees from Ferring for the conduct of this study. Viviana García-Horton, PhD, Analysis Group, Inc.: I am an employee of Analysis Group, Inc., which has received consulting fees from Ferring for the conduct of this study. Mirko Fillbrunn, PhD, Analysis Group, Inc.: I am an employee of Analysis Group, Inc., which has received consulting fees from Ferring for the conduct of this study. Glenn S. Tillotson, PhD, Dynavax: Advisor/Consultant|Ferring Pharmaceuticals: Advisor/Consultant|Peggy Lillis Foundation: Honoraria|Spero Therapeutics: Advisor/Consultant Yipeng Gao, PhD, Merck and Co.: Grant/Research Support Erik R. Dubberke, MD, MSPH, Abbott: Advisor/Consultant|AstraZeneca: Advisor/Consultant|Ferring Pharmaceuticals: Advisor/Consultant|Ferring Pharmaceuticals: Grant/Research Support|Merck and Co.: Advisor/Consultant|Pfizer: Advisor/Consultant|Pfizer: Grant/Research Support|Seres Therapeutics: Advisor/Consultant|Summit: Advisor/Consultant|Theriva Biologics: Grant/Research Support Kevin W. Garey, PharmD, MS, Acurx: Grant/Research Support|Ferring: Advisor/Consultant|Paratek: Grant/Research Support